Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study

MLA

Jingzhu Zhao, et al. “Anlotinib in Patients with Medullary Thyroid Carcinoma with Negative Prognostic Factors: A Sub-Analysis Based on the ALTER01031 Study.” Frontiers in Oncology, vol. 12, Nov. 2022. EBSCOhost, https://doi.org/10.3389/fonc.2022.852032.

APA

Jingzhu Zhao, Yihebali Chi, Chuanxiang Hu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, Jun Wang, Jie Chen, Jiewu Zhang, Ying Cheng, Zhendong Li, Hui Liu, Jianwu Qin, Jingqiang Zhu, Ruochuan Cheng, Zhengang Xu, Dapeng Li, Pingzhang Tang, … Xiangqian Zheng. (2022). Anlotinib in patients with medullary thyroid carcinoma with negative prognostic factors: A sub-analysis based on the ALTER01031 study. Frontiers in Oncology, 12. https://doi.org/10.3389/fonc.2022.852032

Chicago

Jingzhu Zhao, Yihebali Chi, Chuanxiang Hu, Xiaohong Chen, Minghua Ge, Yuan Zhang, Zhuming Guo, et al. 2022. “Anlotinib in Patients with Medullary Thyroid Carcinoma with Negative Prognostic Factors: A Sub-Analysis Based on the ALTER01031 Study.” Frontiers in Oncology 12 (November). doi:10.3389/fonc.2022.852032.